Similar Outcomes of Three Different Treatment Regimens Reported in Multiple Myeloma
the Cancer Therapy Advisor take:
Three salvage infusional chemotherapy regimens produced similar responses, survival, and adverse events in patients with multiple myeloma, according to an article published online in the journal Cancer.
In a single-institution study, three salvage chemotherapy regimens were compared among 107 patients with recurrent multiple myeloma who were treated using one of three salvage chemotherapy regimens.
Fifty-two patients received dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) cohort; 22 received bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide (VTD-PACE) treatment group; and 33 patients received cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD).
There were some differences between groups. For example, patients treated with CVAD had a higher baseline creatinine (P<0.001) and those treated with VTD-PACE had greater prior use of infusional chemotherapy (P<0.001).
Regarding patient response, no significant differences were reported among the three groups (55% overall; P=0.18).
Similarly, no significantly different outcomes were reported for survival among the three groups: overall median progression-free survival of 4.5 months (95% CI: 3.6, 5.5 months; P=0.8) and a median overall survival of 8.5 months (95% CI: 6.1, 11 months; P=0.8). DCEP, VTD-PACE, and CVAD demonstrated similar clinical adverse events; however, it was noted that DCEP was suggested as having fewer events.
Sixty-two percent of patients with the intent to transplant were successfully bridged to transplant without further therapy (P=0.9).
Furthermore, the intent-to-transplant population had greater response outcomes (OR, 3.40; P=0.01), superior progression-free survival (HR, 0.28; P<0.001), and increased overall survival (HR, 0.19; P<0.001).
Three salvage infusional chemotherapy regimens produced similar responses, survival, and adverse events in patients with multiple myeloma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer